Noninvasix Announces Formation of Scientific Advisory Board
Appoints Critical Care Obstetrics Expert, Gary D. Hankins, M.D.
Houston, TX, August 06, 2015 --(PR.com)-- Clinical-stage medical device company Noninvasix, Inc., developers of a fetal welfare monitoring system using patented optoacoustic technology, today established the company’s Scientific Advisory Board. Noninvasix co-founder and technology co-inventor Dr. Donald S. Prough will lead the advisory board in providing objective, external perspective as the company enters human trials and prepares for FDA approval.
The first esteemed member confirmed to the new Board is Gary D. Hankins, M.D., Chairman of the department of Obstetrics and Gynecology at The University of Texas Medical Branch in Galveston. Widely recognized for his contributions in critical care obstetrics, Hankins has worked closely with the American Congress of Obstetricians and Gynecologists in many areas including chairing the 2003 task force, which was responsible for publishing the first edition of ACOG guidelines. In 2014, he served as vice chair of the ACOG task force update reporting on neonatal encephalopathy and neurologic outcome.
While the initial focus of the panel is to review the business development and quality and technical development of the fetal monitoring device, the Board will also advise Noninvasix on other indications for its optoacoustic technology including minimizing cerebral ischemic injuries in preterm infants and in non-invasive monitoring of brain injury.
In addition to Hankins, Noninvasix CEO Graham Randall, Ph.D. will continue to seat the Board with prominent clinical leaders and distinguished experts with complementary, diverse backgrounds, both in academia and industry.
“We are entering a crucial phase of development as we look to build a production prototype, perform clinical trials and obtain FDA approvals in the next 24 months,” said Randall. “We’ve established a solid footprint for success and now the timing is right to surround ourselves with a talented group of advisors such as Dr. Hankins who will engage thoughtfully and provide informed guidance.”
Hankins’ has been the author or co-author on more than 230 articles, 40 book chapters, 10 books and hundreds of abstracts. He has served as the Consultant to the Air Force Surgeon General for Obstetrics/Gynecology since 1995 and The Texas Department of State Health Services appointed him to serve as the Chairman of the Healthy Texas Babies Expert Panel and Resource Team, which is tasked with identifying interventions to support the reduction of infant mortality in Texas.
About Noninvasix, Inc.
Using patented optoacoustic technology, Galveston, Texas-based Noninvasix, Inc. has developed a solution for the safe, accurate and non-invasive monitoring of fetal welfare during labor and delivery. Noninvasix is undertaking to significantly improve outcomes for mother and baby during labor, while reducing malpractice lawsuits and premiums, is backed by 15 years of optoacoustic research, $2 million in funding and more than $6.5 million in research grants. For more information, visit www.noninvasix.com.
The first esteemed member confirmed to the new Board is Gary D. Hankins, M.D., Chairman of the department of Obstetrics and Gynecology at The University of Texas Medical Branch in Galveston. Widely recognized for his contributions in critical care obstetrics, Hankins has worked closely with the American Congress of Obstetricians and Gynecologists in many areas including chairing the 2003 task force, which was responsible for publishing the first edition of ACOG guidelines. In 2014, he served as vice chair of the ACOG task force update reporting on neonatal encephalopathy and neurologic outcome.
While the initial focus of the panel is to review the business development and quality and technical development of the fetal monitoring device, the Board will also advise Noninvasix on other indications for its optoacoustic technology including minimizing cerebral ischemic injuries in preterm infants and in non-invasive monitoring of brain injury.
In addition to Hankins, Noninvasix CEO Graham Randall, Ph.D. will continue to seat the Board with prominent clinical leaders and distinguished experts with complementary, diverse backgrounds, both in academia and industry.
“We are entering a crucial phase of development as we look to build a production prototype, perform clinical trials and obtain FDA approvals in the next 24 months,” said Randall. “We’ve established a solid footprint for success and now the timing is right to surround ourselves with a talented group of advisors such as Dr. Hankins who will engage thoughtfully and provide informed guidance.”
Hankins’ has been the author or co-author on more than 230 articles, 40 book chapters, 10 books and hundreds of abstracts. He has served as the Consultant to the Air Force Surgeon General for Obstetrics/Gynecology since 1995 and The Texas Department of State Health Services appointed him to serve as the Chairman of the Healthy Texas Babies Expert Panel and Resource Team, which is tasked with identifying interventions to support the reduction of infant mortality in Texas.
About Noninvasix, Inc.
Using patented optoacoustic technology, Galveston, Texas-based Noninvasix, Inc. has developed a solution for the safe, accurate and non-invasive monitoring of fetal welfare during labor and delivery. Noninvasix is undertaking to significantly improve outcomes for mother and baby during labor, while reducing malpractice lawsuits and premiums, is backed by 15 years of optoacoustic research, $2 million in funding and more than $6.5 million in research grants. For more information, visit www.noninvasix.com.
Contact
Noninvasix
Anna Halvorson
713-510-0500
Anna Halvorson
713-510-0500
Contact
Multimedia
Dr. Gary D. Hankins
Chairman of the department of Obstetrics and Gynecology at The University of Texas Medical Branch in Galveston
Categories